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Kawasaki syndrome (KS)' is an acute illness of early childhood characterized
by prolonged fever (5 d or longer), diffuse mucosal inflammation, indurative
edema of the hands and feet, polymorphous skin rash, and nonsuppurative
lymphadenopathy (1, 2). This disease has aroused much interest because of its
association with sudden death stemming from coronary arteritis accompanied by
coronary aneurysms and thrombotic occlusion (3, 4). The histopathologic find-
ings in KS indicate a panvasculitis with endothelial necrosis, immunoglobulin
deposition, and the infiltration of mononuclear cells into small- and medium-
sized blood vessels (5, 6). Although much attention has been focused on the
occurrence of coronary artery disease in KS, inflammation of other medium
sized arteries also occurs (7, 8) and venulitis is a prominent finding in studies of
autopsy cases (8).
The acute phase of KS is characterized by marked T cell and B cell activation
(9, 10). The antibody repertoire that is activated in these patients, however, is
poorly defined. Sera from patients with acute KS do not contain the usual
autoantibodies frequently associated with collagen/vascular diseases, i.e., no
rheumatoid factor, antinuclear, or anti-DNA antibodies have been detected (11).
We have recently demonstrated that sera from patients with acute KS contain
IgM antibodies that lyse cultured human umbilical vein endothelial (HUVE) and
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' Abbreviations used in this paper:
￿
HEC, human endothelial cell; HDF, human dermal fibroblast;
HSVE, human saphenous vein endothelial cell; HSVSM, human saphenous vein smooth muscle cell;
HUVE, human umbilical vein endothelial cell; IC, immune complex; KS, Kawasaki syndrome; TNF,
tumor necrosis factor.
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human saphenous vein endothelial (HSVE) cells stimulated for 3-5 d with IFN-
'y, a mediator secreted by activated T lymphocytes (12). Untreated HUVE cells
were not lysed by sera from patients with acute KS. Previous observations have
shown that IFN-y can induce cultured human endothelial cells (HEC) to express
class II major histocompatibility complex (MHC) antigens (13) and cause HEC
to change shape and monolayer organization (14). These changes require 3-5 d
of incubation for maximal effect.
The vascular lesion of acute KS is infiltrated with monocyte/macrophages as
well as activated T lymphocytes. Activated monocyte/macrophages secrete the
mediators IL-1 and tumor necrosis factor (TNF), which induce HEC to express
tissue factor-like procoagulant activity (15, 16) and also induces HEC to become
more adherent for leukocytes (17). Concomitant with these functional changes
in HEC, we have recently demonstrated that TNF and IL-1 can induce HEC to
express a new surface antigen detected by a monoclonal antibody, H4/18 (18).
All these IL-1 or TNF effects are more rapid (peak effect in 4-6 h) than those
mediated by IFN-y, and are transient with loss of cell expression by 24 h,
regardless of the continued presence or absence of monokines .
In the present study, we investigated the possibility that cytotoxic antibodies
to IL-1- or TNF-inducible endothelial cell surface antigens could contribute to
the vascular injury observed during the acute phase of KS. We report here that
IgG and IgM antibodies in acute KS sera cause complement-mediated lysis of
IL-1- or TNF-stimulated HUVE and HSVE cells but not control, IL-I-, or TNF-
stimulated autologous human dermal fibroblasts (HDF) or human saphenous
vein smooth muscle (HSVSM) cells. Furthermore, the target antigen(s) induced
on endothelial cells by IL-1 or TNF differs from the previously described target
antigen(s) induced by IFN-y.
Materials and Methods
Cells.
￿
HUVE cells were isolated by the method of Gimbrone (19) and passaged under
the conditions of Thornton et al. (20). Media, antibiotics, and tissue culture plastic
(Corning) were all obtained from M.A. Bioproducts (Walkersville, MD) ; fetal calf serum
was from Gibco (Grand Island, NY); endothelial cell growth supplement was from Meloy
Laboratories Inc . (Springfield, VA); gelatin was from Difco Laboratories Inc. (Detroit,
MI) and porcine heparin was purchased from Sigma Chemical Co. (St. Louis, MO) . Cells
were used upon serial subculture (passage levels 3-10). HDF were cultured from the
foreskin of a donor whose umbilical cord was used to establish one of the HUVE cell
cultures. HSVE cell and autologous HSVSM cell cultures were a gift of Peter Libby (Tufts
University School of Medicine, Boston, MA).
Sera.
￿
A total of 31 samples of sera were obtained from 20 children with KS (12 boys,
8 girls; mean age, 2.1 yr; age range, 7 mo to 8 yr); 20 samples were obtained during the
acute phase of KS, i .e., within 3 wk of the onset of fever, and I 1 samples were obtained
during the convalescent phase of KS (2-4 mo after resolution of acute symptoms). Seven
patients were studied during both the acute and convalescent phases of their illness. The
criteria used for diagnosis of KS were as previously described (12).
Sera were also obtained from 17 age-matched controls (10 boys, 7 girls; mean age, 2.6
yr; age range, 6 mo to 9 yr); five samples were obtained during evaluations for suspected
allergic rhinitis in the Allergy Clinic at Children's Hospital, Boston, four samples were
obtained during cardiac catheterization for evaluation of noninflammatory congenital
heart disease, and eight samples were obtained from hospitalized patients with fever
(temperature above 38.5°C) owing to bacterial illness (meningitis [n = 4], sepsis [n = 2],
pyelonephritis [n = 1], and pneumonia [n = 1]) .1960 KAWASAKI SERA AND MONOKINE-TREATED ENDOTHELIUM LYSIS
In some experiments, sera from patients with acute KS were subjected to ultracentrif-
ugation at 100,000 g for I h in an Airfuge (Beckman Instruments, Inc ., Fullerton, CA)
to remove any immune complexes present in the sera. In addition, control sera were heat-
treated at 63°C for 1 h to form immune complexes (IC) . The concentration of IC formed
by heat treatment was quantitated by the Clq-binding assay (courtesy of Dr. P. Schur,
Brigham and Women's Hospital, Boston). In selected experiments, acute KS sera were
adsorbed with HUVE cells prestimulated with IL-1, TNF, IFN-y, or control medium in
order to define the nature of the target endothelial cell antigen. In these experiments,
0 .6 ml of acute KS sera (diluted 1 :2.5) was incubated with nonenzymatically suspended
1 .5 X 10' control or mediator-treated HUVE cells for 1 h at 4°C before removing the
cells by centrifugation.
Informed consent was obtained from each patient and/or his/her parents before
performance of the study.
Isolation of Serum IgG and IgM.
￿
Monospecific affinity-purified anti-human IgG and
anti-human IgM antibody was purchased from Tago Inc. (Burlingame, CA). These
antisera were then coupled individually or in combination to CNBr-activated Sepharose
4B as outlined by the manufacturer (Pharmacia Fine Chemicals, Piscataway, NJ). To
isolate serum IgG and IgM, acute KS sera was incubated with Sepharose 4B coupled with
the appropriate antiserum for 2 h at 22 °C on a rotator. The effluent (unbound material)
from each suspension was then collected, the beads were washed extensively with ice-cold
PBS, and the respective immunoglobulin isotype was eluted with 3 M sodium thiocyanate
at 4°C . The eluates and effluents were immediately dialyzed against RPMI culture
medium, adjusted to their original serum volumes, and stored at -80°C until tested .
Purity of the IgG and IgM fractions were demonstrated by the Mancini immunodiffusion
method (Kallestad Laboratories, Inc., Austen, TX).
Monoclonal Antibodies.
￿
The following murine monoclonal antibodies (mAb) were used
during the course of this study: H4/18 (IgGIK, directed against an IL-1- or TNF-
inducible surface endothelial cell antigen) (18), E1/1 .2 (IgG2b, directed against mono-
morphic antigen on mesenchymal cells) U. S. Pober and D. L . Mendrick, unpublished
results), and LB3.1 (IgG2b, directed against an HLA-DR monomorphic determinant)
(21).
Mediators.
￿
Human IL-1, affinity purified by the method of Dinarello from activated
blood monocytes (22) and recombinant IL-1a (23) were purchased from Genzyme (Boston,
MA). Recombinant IL-1,Q (24) was purchased from Cistron (Pinebrook, NJ). Human TNF
was expressed from a cDNA clone in Escherichia coli (25) and was at least 99% pure. The
endotoxin levels in these preparations were <1 ng/ml in the IL-1 stock solution (100
U/ml) and <10 ng/ml in the TNF stock solution (2.5 X 10' U/ml). Human IL-2, IFN-0,
and IFN-y were also used in the form of expressed recombinant products (26-29). IFN-a,
expressed from a synthetic consensus sequence, was purchased from Amgen (Thousand
Oaks, CA).
All of the preparations of mediators used were tested in bioassays, with HEC when
appropriate. Specifically, monocyte-derived IL-1, recombinant IL-la, recombinant IL-I/3
and recombinant TNF all induced HEC-specific expression of H4/18 binding (18). All of
the interferons and TNF modulated HUVE cell expression of MHC antigens (13, 30).
IL-2, which has no described action on HEC, was mitogenic for CTL line cells (31). None
of the mediators at the concentrations or times used appeared toxic for the cultured cells
as judged by loss of trypan blue dye exclusion or inhibition of radioactive amino acid
incorporation into trichloroacetic acid-precipitable protein.
Treatment ofCell Cultures with Mediators.
￿
Mediators were added to various cell cultures
in Medium 199, containing 20% FCS and antibiotics, at the following concentrations:
IFN-y, 200 U/ml; IL-I, 5 U/ml; TNF, 50 U/ml; IFN-a, 1,000 U/ml; IFN-,B, 1,000 U/ml ;
and IL-2, 100 U/ml. Incubations continued for the times indicated in each experiment.
In endothelial cytotoxicity experiments, the effectiveness of IL-1 or TNF treatment
was monitored by the induction of H4/18 mAb binding on replicate cultures using a
radioimmunoassay (18). The appearance of cell surface class II MHC antigen was used to
confirm that IFN-y treatment was effective. The latter cell surface antigen was detected1961
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FIGURE 1 .
￿
Cytotoxic effects of acute KS sera on cultured endothelial cells. Untreated (A),
IL-1-treated (B) or TNF-treated (L) "'In-labeled HUVE cells pretreated for 4 h with control
medium (A), IL-1 (B), or TNF (C) were sequentially incubated with a 1:2.5 dilution of sera
from patients with acute KS, convalescent KS, or normal controls, followed by a i:l dilution
of rabbit serum. The percent specified "'In release was determined. The mean ± 1 SD for
each group is shown. Each solid circle is the mean result ofan individual serum performed in
triplicate. For sera tested on more than one occasion,themean value for percent "'In release
obtained from these multiple determinations is shown.
both with an "'In-release cytotoxicity assay using class II mAb (LB3.1) plus complement
and by radioimmunoassay.
Detection of Cytotoxic Antibodies in Human Sera.
￿
An "'In-release assay was used to
detect cytotoxic anti-endothelial (HUVE or HSVE) cell, anti-smooth muscle (HSVSM)
cell, or antifibroblast (HDF)antibodies in KS patientor control sera as previously described
(12). Percent specific release (SR) was calculated as follows: (cpm experimental - cpm
spontaneous)/(cpm total - cpm spontaneous). In each experiment, treatment with mAb
E1/1 .2 plus complement wasused to establishmaximal radioactivity that couldbe released.
After cytolysis with mAb E1/1 .2, the entire target cell population shows morphologically
detectable damage, and the release of radioactivityinto the culture medium is comparable
to that obtained with detergent, e.g., NP-40, treatment.
Statistics.
￿
Comparison between the cytotoxic effects of patient and control sera were
carried out using the nonparametric Wilcoxon rank-sum test. The results are expressed
as the mean ± SD.
Cytolysis of Vascular Endothelium Treated with IL-1, TNF, and OtherMediators by
Sera from Patients with Acute KS. Sera from 20 patients in the acute phase of
KS, 11 patients in the convalescent phase of KS, and 17 age-matched controls, 8
of whom had other febrile illnesses, failed to cause any significant "' In release
(p > 0.2) from untreated HUVE cultures (Fig. lA). In contrast, sera obtained
from the same group of patients with acute KS resulted in significantly higher
LEUNG ET AL.
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"`In release (30.5 ± 11.8; p < 0.01) from HUVE preincubated with monocyte-
derived IL-1 for 4 h than did sera from age-matched controls (1 .0 ± 2.1% "'In
release) as calculated by the Wilcoxon rank-sum test. All 20 acute KS sera caused
"' In release that was >2 SD above the mean value (i.e., > 5.2%) obtained using
control sera (Fig. 1B). None of the I 1 sera obtained from the convalescent phase
of KS caused "'In release greater than the normal range. The mean percent
"' In release caused by convalescent KS sera was not significantly different (1 .1
± 1.0; p > 0.2) than that obtained with normal sera and was significantly (p <
0.1) less than that caused by acute KS sera. Comparable susceptibility to lysis by
acute KS sera could be induced with either recombinant human IL-la or IL-10
polypeptides (results not shown).
TNF, like IL-1, has also been shown to induce new endothelial cell surface
antigens within a 4-h incubation period (18). We, therefore, tested the cytotoxic
effect of sera from the same three patient populations on endothelial cells
pretreated with TNF for 4 h. The data in Fig. 1 C indicate that sera from
patients with acute KS, but not sera from control patients or patients in the
convalescent phase of KS, lysed TNF-stimulated HUVE (p < 0.01). The effects
of IL-1 and TNF on HUVE appear specific because acute KS sera failed to lyse
HUVE cells preincubated for 4 or 72 h with IFN-y, IFN-0, or IL-2 (results not
shown) .
Characterization ofSerum Cytotoxic Activity in KS.
￿
Sera from patients with acute
KS were studied for the complement dependence of the cytotoxic effects on
IL-1- or TNF-treated HUVE cells. In these experiments, "'In-labeled IL-1 or
TNF-treated HUVE cells were initially incubated with sera from patients with
acute KS. Subsequently, fresh rabbit serum or heat-treated (56°C for 1 h) rabbit
serum was added to the cultures. "'In release was observed only when fresh
rabbit serum, but not heat-inactivated rabbit serum, was added to IL-1- or TNF-
treated HUVE cells preincubated with KS sera (results not shown).
Because circulating IC have been reported in patients with acute KS (32), we
investigated the possibility that the observed complement-dependent cytotoxic
effects ofacute KS sera were beingmediated via IC. The data in Table I indicates
that, after centrifugation at 100,000 g to sediment IC, sera from acute KS
patients continued to maintain the same level ofantiendothelial cytotoxic activity
as untreated sera. Furthermore, the formation of IC in normal sera by heat
treatment (quantitated by Clq binding) was not associated with any detectable
increase in endothelial cell cytotoxic activity .
The immunoglobulin class ofcytotoxic anti-endothelial cell antibodies in acute
KS was determined by passing serum from patients with acute KS through anti-
human immunoglobulin-conjugated Sepahrose4B columns. The results in Table
II indicate that, when acute KS sera was absorbed with anti-human IgM Sepha-
rose, both the effluent as well as the eluate fraction contained cytotoxic anti-
endothelial cell activity. Similar results were obtained when acute KS sera was
passed through anti-human IgG-conjugated columns. These data suggest that
the cytotoxic antiendothelial activity in acute KS sera are associated with both
the IgG and IgM antibody fraction. To exclude the possibility that a non-
immunoglobulin fraction also mediated cytotoxicity, we passed acute KS sera
over Sepharose conjugated with both anti-human IgG and anti-human IgM. AsTABLE I
Cytotoxic Effect ofAcute KS Sera Is Not Mediated through Immune Complexes
Sera from two patients with acute KS were centrifuged at 100,000 g for 1 h in a
Beckman Airfuge, and the serum supernatants were compared with untreated sera for
their ability to lyse "' In-labeled untreated, IL-1-treated, or TNF-treated HUVE cells
(4-h treatments). Serum from a normal donor containing <20 ng IgG IC/ml was
incubated at 63°C for 1 h to form IC and compared with the untreated serum for its
ability to lyse untreated HUVE cells or HUVE cellstreated for 4h with either IL-1 or
TNF. After heat treatment, the normal serum contained 2,300 ng/ml of IgG IC as
measured by the Clq binding assay. Data were calculated from means of triplicate
determinations; all SD were <10%.
TABLE II
Cytotoxic Effects ofAcute KS Sera on IL-1- or TNF-stimulated HUVE Cells Is Mediated
through IgG and IgM Antibodies
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Sera from six patients with acute KS (exp. 1 and exp. 2 each used a pool of sera from threedonors)
were fractionated by adsorption over anti-human IgGor anti-human IgM Sepharoseor Sepharose
conjugated with anti-human IgG and anti-human IgM. The effluent and eluate fractions of these
columns were added to "'In-labeled HUVE cell cultures pretreated with either IL-1 or TNF for
4 h, and "'In release was measured after treatment with rabbit complement as described in
Materials and Methods.
* These data were collected from a separate assay using the same pooled sera. Data were expressed
as percent specific "' In release and calculated from the mean of triplicate determinations; all SD
were <10% .
Serum adsorption
IL-1-treated
Exp. 1
HUVE
Exp. 2
TNF-treated
Exp. I
HUVE
Exp. 2
Unadsorbed 25.9 45.3 33.5 64.7
Anti-IgG Sepharose
Effluent 17.6 38 .5 19.5 42.8
Eluate 8.9 17 .2 18.8 27.6
Anti-IgM Sepharose
Effluent 10.3 13 .9 12.5 31 .2
Eluate 22.2 44.1 30.8 40.6
Anti-IgG/anti-IgM Sepharose*
Effluent 0 0 0.8 0
Eluate 39.8 66.2 42.6 51 .0
Serum donor Treatment
Percent
Without
mediator
specific "'In
With
IL-1
release
With
TNF
KS I Untreated 0.7 32.1 32.9
100,000 g centrifugation 0.6 31 .6 31 .7
KS II Untreated 0 24.1 23.6
100,000 g centrifugation 0 24.0 23.2
Normal Untreated 0.2 0.4 0
Heat treated 0 0 01964 KAWASAKI SERA AND MONOKINE-TREATED ENDOTHELIUM LYSIS
TABLE III
Acute KS Sera Lyse IL-1- or TNF-treated HUVE CellsButNot IL-1-
or TNF-treated Dermal Fibroblasts (HDF) Derivedfrom
the Same Donor
Sera from three different patients with acute KS were tested for comple-
ment-dependent cytotoxic effects on HUVE cells and HDF derived from
the same donor. Both cell types were pretreated for 4 h with control
medium or medium containing IL-1 or TNF. Data were calculated as the
means of triplicate determinations; all SD were <10%.
shown in Table II, the cytotoxic activity was restricted to the IgG and IgM
fraction of acute KS sera.
Antibodies in Acute KS Lyse IL-1- or TNF-stimulated HUVE or HSVF, Cells But
Not IL-1- or TNF-stimulated HDF or HSVSM. The target specificity of cytotoxic
anti-endothelial cell antibodies in acute KS was further examined by assessing
the ability of sera from patients with acute KS to lyse control-treated, IL-1-
treated, or TNF-treated HDF. As shown in Table III, three different acute KS
sera were capable of lysing IL-1- or TNF-treated HUVE but failed to cause lysis
of either control-treated, IL-1-treated, or TNF-treated HDF. These results were
not due to allotypic differences that might occur between unrelated donors of
HUVE cells and HDF because the HUVE cells and HDF used in Table III were
derived from the same donor.
We further examined whether sera from acute KS were cytotoxic to HSVF
vs. HSVSM cells. As shown in Table IV, four different acute KS sera lysed IL-I-
or TNF-treated HSVE but not control-treated HSVE cells, control-treated
HSVSM, IL-1-treated HSVSM, or TNF-treated HSVSM cells.
IL-1- or TNF-inducibleEndothelial Target Antigen Is Rapidly ButOnly Transiently
Expressed. Previous studies investigating mediator-induced synthesis of new
endothelial cell proteins have found that IFN--y requires 3-5 d for peak expres-
sion of class II MHC expression (13) whereas IL-1 or TNF only requires 4-6 h
to maximally induce HEC to express procoagulant activity (15, 16), leukocyte
adherence (17), or reactivity with the H4/18 mAb (18). We therefore examined
the capacity of acute KS sera to lyse "' In-labeled HUVE pretreated with control
medium or medium containing IL-1, TNF, and IFN--y for the following time
periods: 4, 24, and 72 h.
The data shown in Table V indicate that HUVE become susceptible to lysis
within 4 h of incubation with IL-1 or TNF. This effect, however, was not
observed when the same HUVE were preincubated for 24 or 72 h with IL-1 or
Target cells KS sera
donor
Percent
Without
mediator
specific "'In
With IL-1
release
With TNF
HUVE 1 0 35.6 37.8
HUVE 2 0 33.2 24.3
HUVE 3 0 28.3 29.8
HDF 1 1 .3 1 .1 0
HDF 2 1 .4 0 0
HDF 3 1 .4 0.8 1 .1TABLE IV
Acute KS Sera Lyse IL-1- or TNF-treated Endothelial Cells But Not
IL-1- or TNF-treated Smooth Muscle Cellsfrom Saphenous Vein of
the Same Donor
Target cells
LEUNG ET AL.
TABLE V
HSVE
HSVSM
Sera from patients with acute KS were tested for complement-dependent
cytotoxic effects on passaged HSVE and HSVSM cells derived from the
same segment of the human saphenous vein. Both cell types were pre-
treated for 4 h with either control medium or medium containing IL-1 or
TNF.
Time Course ofMediator-induced Endothelial Target Expression
Four sera, one from a control subject and three from patients with acute
KS, were tested for their capacity to lyse HUVE cells treated with control
medium or medium containing either IL-1,TNF, or IFN-,yforthreetime
intervals: 4, 24,or 72 h. Data areexpressedas percentspecific "'In release
and calculated from the mean of triplicate determinations; all SD were
<10% .
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TNF. In contrast, HUVE required 72 h of incubation with IFN-^y before they
became susceptible to lysis with acute KS sera. No significant lysis of HUVE was
observed when they were preincubated with IFN-y for 4 or 24 h.
HUVE
Duration
(h)
treatment
Mediator Control
Sera
KS 1
tested
KS 2 KS 3
4 None 0 5.7 4.6 5.0
IFN--y 0 0 0 0
IL-1 0 33.4 29.0 27 .9
TNF 0 29.2 31 .0 25.8
24 None 4.4 5.2 2.6 2.7
IFN--y 0 4.9 6.2 8.7
IL-1 0 3.4 3.7 3.2
TNF 0 2.6 4.6 2.8
72 None 0 0 0 0
IFN-y 0 17.9 29 .9 21 .9
IL-1 0 4.1 6.4 8.4
TNF 0 4.9 8.9 5.0
KS sera
donor
Percent
Without
mediator
specific "'In
With IL-1
release
With TNF
1 0.8 47.5 39.6
2 0 29.3 19.6
3 0.7 45.9 43.2
4 1.1 28.7 33.6
1 1.1 0.7 1.4
2 1.6 1.1 1.5
3 0.8 2.0 2.6
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TABLE VI
IL-1- or TNF-inducible Endothelial Target Antigen Recognized by AcuteKS Sera
Is Distinctfrom the IFN-y-inducible Target Antigen
Discussion
A pool ofsera from three patients with acute KS was preincubated with either untreated
HUVE cells, HUVE cells treated with IFN-y for 72 h, HUVE cells treated with IL-1
for 4 h, or HUVE cells treated for 4 h with TNF, as described in Materials and Methods.
Subsequently, these adsorbed sera were tested for their capacity to lyse "'In-labeled
HUVE cells treated either with control medium or HUVE cells stimulated with IFN-y
for 72 h, IL-1 for 4 h, or TNF for 4 h. Data are expressed as percent specific "`In
release and calculated from the mean of triplicate determinations; all SD were <10%.
Distinction of the IL-1- or TNF-inducible Target Endothelial Antigenfrom theIFN-
-y-inducible Antigen. The different preincubation periods required by IFN-'y vs.
IL-1 or TNF for rendering HUVE cells susceptible to lysis by acute KS sera
strongly suggested that IFN-y induced an endothelial cell target antigen(s)
distinct from those induced by IL-1 or TNF. To compare further the nature of
endothelial cell antigens induced by these three mediators, we tested the capacity
of acute KS sera to lyse HUVE cells treated with IFN-y for 72 h after adsorption
with human control HUVE cells, IFN-y-treated HUVE cells, HUVE cells treated
for 4 h with IL-1, or HUVE cells treated for 4 h with TNF. The results in Table
VI indicate that IFN-y-treated HUVE cells effectively absorbed out cytotoxic
anti-endothelial cell activity against IFN-y-stimulated HUVE cells. In contrast,
neither control-treated HUVE cells nor IL-1- or TNF-stimulated HUVE cells
removed the cytotoxic activity of acute KS sera directed against IFN-y-treated
HUVE cells. Similarly, when acute KS sera were absorbed with IL-1 or TNF
stimulated HUVE cells they were no longer cytotoxic to either IL-1- or TNF-
treated HUVE cells. However, acute KS sera absorbed with IFN-y-treated HUVE
cells or control-treated HUVE cells continued to manifest cytotoxic activity
against IL-1- or TNF-treated HUVE cells. The data in Table VI also indicate
that IL-1 and TNF induce similar endothelial target antigens because absorption
of acute KS sera with IL-1-treated HUVE cells removed the cytotoxic activity
directed against TNF-treated HUVE cells and vice versa.
Vascular endothelial cells are known to be targets for the actions of immune
mediators. IL-1 was first noted to alter the surfaceof HEC by inducing expression
of tissue factor-like procoagulant activity (15). IL-1 also increases HEC adhe-
siveness for polymorphonuclear leukocytes (17, 33), blood monocytes (17), and
lymphocytes (34). IL-1 may additionally affect coagulation by increasing biosyn-
thesis of prostacyclin (35) and platelet-activating factor (36), decreasing the
generation of activated protein C (37), and increasing secretion of the specific
Adsorbent
None
HUVE target
IFN-y
(3 d)
cell treatment
IL-1
(4 h)
TNF
(4 h)
None 1 .0 26.1 18.6 26.1
Control HUVE cells 0 18.4 19.2 20.9
IFN-y-treated HUVE cells 0 _0.7 25.3 30 .0
IL-1-treated HUVE cells 0 13.6 _3.6 _4.4
TNF-treated HUVE cells 0 15.5 0 3 .5LEUNG ET AL.
￿
1967
inhibitor of plasminogen activator (38-40). With the exception of prostacyclin
synthesis, all of these actions would be expected to promote coagulation and
inflammation. Furthermore, the generation of thrombin, through a tissue factor-
activated procoagulant pathway, can cause HEC to release IL-1, potentially
amplifying the inflammatory effects (41). TNF has been shown to act on HEC,
increasing expression of class I MHC antigens (42) and causing HEC cultures to
undergo a morphologic rearrangement that may facilitate transendothelial
trafficking of leukocytes (14). Interesting, TNF shares a number of actions with
IL-1, causing both an increase in HEC adhesiveness for leukocytes (43) and an
induction of tissue factor-like procoagulant activity (16, 44). TNF also induces
the release of IL-1 by HEC (45) . The procoagulant and proinflammatory actions
of TNF, by promoting vascular thrombosis and leukocytic infiltration, may
contribute to the action of this mediator in causing hemorrhagic necrosis of
tumors.
Many of the actions of IL-1 and TNF appear to involve modulation of HEC
surface molecules. In fact, a monoclonal antibody raised to IL-1-stimulated
HUVE cells detects a protein antigen the expression of which is inducible by
treatment with IL-I or with TNF (18). Previously, we had found that patients
with KS had circulating antibodies directed to HEC antigens induced by IFN-'y.
The present study was undertaken to test the hypothesis that antibodies directed
to IL-1- or TNF-inducible endothelial cell surface antigens may contribute to
the vascular damage observed during the acute phase of KS. Our current
investigation demonstrates that IgG and IgM antibodies in sera from patients
with acute KS lyse cultured HUVE or HSVE cells treated for 4 h with IL-1 or
TNF but do not lyse control-treated HUVE or HSVE cells (Fig. 1). In contrast,
sera from patients in the convalescent phase of KS, or age-matched controls,
including eight patients with other febrile illnesses, failed to lyse either control-
treated or monokine-treated endothelial cells. This complement-mediated cyto-
toxicity activity found in acute KS sera against vascular endothelial cells appears
specific because these KS sera failed to lyse IL-1- or TNF-stimulated HDF or
HSVSM cells autologous to the HEC. Preincubation of HUVE cells with other
mediators such as IFN-a, IFN-,0, IFN-y, or IL-2 for 4 h failed to render HUVE
susceptible to lysis with sera from acute KS.
In a recent study, we demonstrated that sera from patients with acute KS
contain IgM antibodies cytotoxic to IFN-y stimulated HUVE cells (12). The
target endothelial antigen on IFN-y-stimulated HUVE cells was not identified
because these sera were unable to immunoprecipitate IFN-y-induced HUVE cell
proteins. However, it was found that acute KS sera could not lyse IFN-y-
stimulated HDF or vascular smooth muscle cells. Because IFN-y induced the
same level of class I or class II MHC antigen expression on HDF, smooth muscle
cells, and endothelial cells, the target antigens recognized by acute KS sera were
thought not to be MHC determinants. This conclusion was further strengthened
by the observation that, when acute KS sera was absorbed with IFN-y-treated
HUVE cells, B cells, monocytes, T cells, or erythrocytes, only IFN-y-treated
HUVE cells removed the cytotoxic anti-endothelial cell activity .
The IL-1- or TNF-inducible target endothelial cell antigen(s) described in the
current studyappear to be distinct from the previously described IFN-y-inducible1968 KAWASAKI SERA AND MONOKINE-TREATED ENDOTHELIUM L1'SIS
target antigen. This statement is supported by three observations. First, the time
course for induction of target antigen expression by IL-1 or TNF differed from
that seen for IFN--y. The IL-1- or TNF-inducible effects on endothelial cells
were rapid, occurring within 4-6 h, and transient, disappearing after 24 h of
incubation with IL-1 or TNF, even in the continued presence of mediator. In
contrast, the effects of IFN-y were much slower, requiring 72 h to induce its
effect on endothelial cells (Table V). These time intervals correlate with the
optimal incubation periods required for the expression of other previously
described inducible endothelial cell proteins by these mediators (18, 30). Second,
antibodies reactive with IFN-y-stimulated HUVE cells appeared to be exclusively
of the IgM class (12), whereas some the antibodies reactive with IL-1- and TNF-
stimulated cells are of the IgG class. The basis for this difference is unknown.
Third, IFN-y-treated HUVE cells but not IL-1-treated HUVE cells, TNF-treated
HUVE cells, or control-treated HUVE cells were able to absorb out cytotoxic
activity in acute KS were directed against IFN-y-stimulated HUVE cells. The
converse was also true: IL-1- or TNF-treated HUVE cells but not IFN-,y-treated
HUVE cells effectively absorbed out cytotoxic activity in acute KS sera directed
against IL-1- or TNF-stimulated HUVE cells.
In vivo, both types of antigens may be expressed at the same time. The highly
immunogenic nature of vascular endothelial cells (reviewed in Pober et al.
[46]) may contribute to the development of these autoantibodies. IL-I and TNF
seemed to induce similar endothelial cell target antigen(s) because IL-1-treated
HUVE cells removed the cytotoxic activity in acute KS sera directed against
TNF-stimulated HUVE cells and vice versa: absorption of acute KS sera with
TNF-stimulated HUVE cells removed its cytotoxic activity against IL-1-stimu-
lated HUVE cells. There is no possibility that these shared activities of IL-1 and
TNF are due to mediator crosscontamination inasmuch as these effects are
observed with recombinant monokines. These data extend the parallel actions
of IL-1 and TNF on vascular endothelial cells previously noted (16, 18).
The reason for the disappearance of cytolytic antibodies to both IFN-y or
IL-1/TNF-induced antigens during the convalescent phase of KS is not known.
It is possible that the decline in titer represents a fall in antibody level because
of loss of antigenic stimulation (i.e., diminution of the expression ofendothelial
cell activation antigens), or active downregulation of antibody synthesis (e.g.,
suppression) or both. Alternatively, becauseourassay depends upon complement-
mediated lysis, the appearance of antibodies that fail to fix complement, either
by isotype switching or activation of different B cell clones, could lead to
protective or "blocking" antibodies. Blocking antibodies could either mask the
continued presence of cytolytic antibodies or, if of higher affinity, lead to
inactivation of the original B cell populations.
The exact nature of the IL-1- or TNF-inducible endothelial target antigen(s)
is presently unknown. Our attempts to immunoprecipitate IL-1- or TNF-induc-
ible endothelial proteins with acute KS sera from HUVE cells metabolically
labeled with [s5S]methionine have not, to date, been successful . The basis for
this difficulty is not known but may be related to the poor antigen avidity of
naturally occurring antibodies, or alternatively, because the antibodies in acute
KS could be directed to inducible cell surface carbohydrate moieties that cannotLEUNG ET AL.
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be labeled with radiolabeled amino acid precursors. These considerations are
currently under investigation . In any event, the relevant antigenic determinants
appear to be nonpolymorphic because KS sera have lysed HUVE and and HSVE
cells from over five separate donors in the course of these experiments.
The observations made in our present study that patients with acute KS have
circulating cytotoxic antibodies against IL-1- or TNF-stimulated endothelial cells,
along with our previous report that sera from these patients contain antibodies
directed against IFN--t-inducible endothelial antigens, suggest the possibility that
immune activation accompanied by the secretion of mediators are an important
predisposing condition for the development of vascular damage. Indeed, we
have recently examined PBMC from a small number of patients with acute KS
for their capacity to secrete IL-1, as determined by the D10.G4.1 costimulator
assay (47). PBMC from all three patients with acute KS studied but not age-
matched control patients have been found to spontaneously secrete abnormally
high levels of IL-I (Leung and Pober, unpublished observations). Most vasculi-
tides are characterized by polyclonal B cell activation and marked immune
activation with the secretion of mediators. Thus, although our studies have
focused exclusively on KS, we hypothesize that the production of cytotoxic
antibodies directed to mediator-induced endothelial cell antigens may be a novel,
previously unrecognized mechanism for vascular damage in other diseases as
well.
Summary
Kawasaki syndrome (KS) is an acute febrile illness of early childhood charac-
terized by diffuse vasculitis and marked immune activation. The present study
was undertaken to determine whether the acute phase of KS is associated with
circulating cytotoxic antibodies directed to target antigens induced on vascular
endothelium by the monokines, IL-1, or tumor necrosis factor (TNF). Sera from
20 patients with acute KS, 11 patients in the convalescent phase of KS, and 17
age-matched controls were assessed for complement-dependent cytotoxic activity
against '"In-labeled human endothelial cells (HEC), dermal fibroblasts, and
vascular smooth muscle cells. Sera from patients with acute KS but not the other
subject groups caused significant (p < 0.01) complement-mediated killing of
IL-1- or TNF-stimulated HEC. None of the sera tested had cytotoxicity against
control HEC cultures or the other target cell types, with or without IL-1 or TNF
pretreatment.
Expression of the IL-1- or TNF-inducible target antigens on endothelial cells
was rapid and transient, peaking at 4 h and disappearing after 24 h despite
continued incubation with monokine. In contrast, we have previously shown that
IFN-^t requires 72 h to render HEC susceptible to lysis with acute KS sera. Serum
adsorption studiesdemonstrated that IL-1-and TNF-inducible endothelial target
antigens are distinct from IFN--y-inducible antigens. These observations suggest
that mediator secretion by activated monocyte/macrophages could be a predis-
posing factor to the development of vascular injury in acute KS . Although our
present observations have been restricted to KS, the development of cytotoxic
antibodies directed to monokine-inducible endothelial cell antigens may also be
found in other vasculitides accompanied by immune activation.1970 KAWASAKI SERA AND MONOKINE-TREATED ENDOTHELIUM LYSIS
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